Intellia Therapeutics, a Cambridge, MA-based gene-editing company focused on the development of curative medicines using CRISPR/Cas9 technology, closed a Series B round with $70m in additional financing.
The round was led by OrbiMed HealthCare Fund Management with participation from additional investors Fidelity Management and Research Company, Atlas Venture, Novartis, Janus Capital Management, Foresite Capital, Sectoral Asset Management, EcoR1 Capital and other mutual fund and healthcare investors. In conjunction with the financing, Carl L. Gordon, Ph.D., a founding Partner and Co-Head of Global Private Equity at OrbiMed, will join the Intellia Board of Directors.
The company intends to use the proceeds to accelerate the development of its pipeline, expand its platforms for gene editing and delivery, as well as to continue to strengthen its intellectual property portfolio.
Led by Nessan Bermingham, Ph.D., Founder and Chief Executive Officer, and John Leonard, M.D., Chief Medical Officer, Intellia Therapeutics is building a product-driven biotechnology company. The company is focused on the development of proprietary human therapeutics using the CRISPR/Cas9 technology to create a potential new drug class with broad in vivo and ex vivo applications.